-
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis
van den Berg, S. P. H., Toorop, A. A., Hooijberg, F., Wolbink, G., Voelkner, N. M. F., Gelissen, L. M. Y., Killestein, J., van Kempen, Z. L. E., Dorlo, T. P. C. & Rispens, T., Jun 2025, In: CPT: Pharmacometrics and Systems Pharmacology. 14, 6, p. 1032-1041 10 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Gelissen, L. M. Y., Toorop, A. A., Schipper, P. M., Hoitsma, E., Zeinstra, E. M. P. E., van Rooij, L. C., van Munster, C. E. P., Vennegoor, A., Mostert, J., Wokke, B., Kalkers, N. F., Hoogervorst, E. L. J., van Eijk, J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L. G. F. & Kloosterziel, M. E. & 11 others, , 25 Mar 2025, (E-pub ahead of print) In: Journal of neurology, neurosurgery, and psychiatry.Research output: Contribution to journal › Article* › Academic › peer-review
-
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Toorop, A. A., Wessels, M. H. J., Boonkamp, L., Gelissen, L. M. Y., Hoitsma, E., Zeinstra, E. M. P., van Rooij, L. C., van Munster, C. E. P., Vennegoor, A., Mostert, J. P., Wokke, B. H. A., Kalkers, N. F., Hoogervorst, E. L. J., van Eijk, J. J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J. & Sinnige, L. G. F. & 12 others, , Nov 2024, In: Multiple Sclerosis Journal. 30, 13, p. 1683-1688 6 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
